BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29909018)

  • 1. Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody, mepolizumab.
    Suzaki I; Kimura Y; Tanaka A; Hirano K; Ishibashi A; Mizuyoshi T; Ando I; Kitajima T; Watanabe S; Hinohira Y; Kobayashi H
    Auris Nasus Larynx; 2019 Feb; 46(1):141-146. PubMed ID: 29909018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
    Iino Y; Takahashi E; Ida S; Kikuchi S
    Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report.
    van der Lans RJL; van Spronsen E; Fokkens WJ; Reitsma S
    Laryngoscope; 2021 Dec; 131(12):2649-2651. PubMed ID: 34216146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors associated with severity of eosinophilic otitis media.
    Kanazawa H; Yoshida N; Yamamoto H; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Iino Y
    Auris Nasus Larynx; 2014 Dec; 41(6):513-7. PubMed ID: 25199747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media.
    Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
    Acta Otolaryngol; 2014 Apr; 134(4):366-72. PubMed ID: 24628335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma.
    Iino Y; Sekine Y; Yoshida S; Kikuchi S
    Auris Nasus Larynx; 2021 Jun; 48(3):353-360. PubMed ID: 32943257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eosinophilic inflammation in the middle ear induces deterioration of bone-conduction hearing level in patients with eosinophilic otitis media.
    Iino Y; Usubuchi H; Kodama K; Kanazawa H; Takizawa K; Kanazawa T; Ohta Y
    Otol Neurotol; 2010 Jan; 31(1):100-4. PubMed ID: 19816234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of IL-5 Inhibitor Benralizumab as a Novel Therapy for Eosinophilic Otitis Media: Clinical Capsule and Review of Literature.
    Chow K; Cosetti MK
    Otol Neurotol; 2020 Feb; 41(2):e238-e240. PubMed ID: 31923159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophilic Otitis Media Treated with Anti-IgE Monoclonal Antibodies and A Bone Conduction Implant.
    Han YE; Kang YS; Cho Y; Park MK
    J Int Adv Otol; 2018 Apr; 14(1):144-147. PubMed ID: 29764789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eosinophil chemoattractants in the middle ear of patients with eosinophilic otitis media.
    Iino Y; Kakizaki K; Katano H; Saigusa H; Kanegasaki S
    Clin Exp Allergy; 2005 Oct; 35(10):1370-6. PubMed ID: 16238798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
    Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophilic otitis media; state-of-the-art diagnosis and treatment.
    Iino Y
    Auris Nasus Larynx; 2023 Aug; 50(4):479-489. PubMed ID: 36528403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone conduction hearing level in patients with eosinophilic otitis media associated with bronchial asthma.
    Iino Y; Usubuchi H; Kodama K; Takizawa K; Kanazawa T; Ohta Y
    Otol Neurotol; 2008 Oct; 29(7):949-52. PubMed ID: 18758390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Insights into Eosinophilic Otitis Media.
    Kanazawa H; Yoshida N; Iino Y
    Curr Allergy Asthma Rep; 2015 Dec; 15(12):76. PubMed ID: 26546407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of instillation of triamcinolone acetonide into the middle ear for eosinophilic otitis media associated with bronchial asthma.
    Iino Y; Nagamine H; Kakizaki K; Komiya T; Katano H; Saruya S; Kodera K
    Ann Allergy Asthma Immunol; 2006 Dec; 97(6):761-6. PubMed ID: 17201235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eosinophilic otitis media: a new middle ear disease entity.
    Iino Y
    Curr Allergy Asthma Rep; 2008 Nov; 8(6):525-30. PubMed ID: 18940145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease.
    Iino Y; Tomioka-Matsutani S; Matsubara A; Nakagawa T; Nonaka M
    Auris Nasus Larynx; 2011 Aug; 38(4):456-61. PubMed ID: 21251776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of eosinophilic otitis media with pegylated interferon-α 2a and 2b.
    Neff BA; Voss SG; Carlson ML; O'Brien EK; Butterfield JH
    Laryngoscope; 2017 May; 127(5):1208-1216. PubMed ID: 27667784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
    Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.